Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in pediatric systemic juvenile idiopathic arthritis with active systemic features
NL-OMON51984Phase 3Withdrawn
- Sponsor
- Syneos Health
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Syneos Health. Primary endpoint: Time to sJIA disease flare. Planned start Dec 2020; status: withdrawn.
02
Drugs
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NL-OMON51984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51984.